Comparison of pharmacokinetic profiles of a 17β-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state

Maturitas

Volumn 40, Issue 3, 2001, Pages 203-209

  Paoletti, A M ^a   Pilia, I ^a   Nannipieri, F ^b   Bigini, C ^b   Melis, G B ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b AbiogenPharma   (Italy)

Author keywords

17 estradiol; Estraderm TTS 50; Percutaneous treatment

Indexed keywords

ESTRADIOL; ESTRONE; GELESTRA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MEASUREMENT; NORMAL HUMAN; OVARIECTOMY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STEADY STATE;

ADMINISTRATION, CUTANEOUS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTRONE; FEMALE; GELS; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 0035861503     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(01)00239-0     Document Type: Article

References (22)

1. Estrogen therapy during menopause
2. Current concepts in estrogen replacement therapy in the menopause
3. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
4. Menopausal estrogen therapy and hip fractures
5. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
6. Urogenital and vasomotor symptoms in relation to menopausal status and the use of hormone replacement therapy (HRT) in healthy women during transition to menopause
7. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
8. Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys
9. Hormone replacement therapy and cardiovascular disease
10. Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime
11. Lipid-independent therapeutic properties of transdermal 17β-estradiol on cardiovascular diseases
12. Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment
13. Alternatives to oral estrogen replacement
14. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure
15. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women
16. Neuroendocrine and clinical effects of transdermal 17β-estradiol in postmenopausal women
17. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study
18. Adverse skin reactions to transdermal oestradiol in tropical climate. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women
19. Presentation of results from bioequivalence studies
20. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
21. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol
22. Absorption and bioavailability of estradiol from a gel, a patch and a tablet